Safety and Immunogenicity of a Self-Amplifying RNA Vaccine Against Crimean-Congo Hemorrhagic Fever

PHASE1RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

July 10, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

July 31, 2027

Conditions
VaccineCrimean-Congo Hemorrhagic Fever
Interventions
BIOLOGICAL

10 ug HDT 321

HDT-321 Investigational Vaccine (a Nanoparticle Carrier-Formulated self-amplifying RNA encoding the NP of CCHFV)

BIOLOGICAL

25ug HDT-321

HDT-321 Investigational Vaccine (a Nanoparticle Carrier-Formulated self-amplifying RNA encoding the NP of CCHFV)

BIOLOGICAL

50ug HDT-321

HDT-321 Investigational Vaccine (a Nanoparticle Carrier-Formulated self-amplifying RNA encoding the NP of CCHFV)

Trial Locations (1)

78229

RECRUITING

Flourish Research San Antonio (Clinical Trials of Texas), San Antonio

All Listed Sponsors
collaborator

DFNet Research Inc.

OTHER

collaborator

Technical Resources International, Inc. (TRI)

UNKNOWN

collaborator

BioAgilytix Labs, LLC

UNKNOWN

collaborator

The University of Texas Medical Branch, Galveston

OTHER

collaborator

Clinical Trials of Texas, Inc.

OTHER

collaborator

Quest Laboratories

UNKNOWN

lead

HDT Bio

INDUSTRY

NCT06799013 - Safety and Immunogenicity of a Self-Amplifying RNA Vaccine Against Crimean-Congo Hemorrhagic Fever | Biotech Hunter | Biotech Hunter